Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in children with chronic-phase FIRES
ChiCTR2400085185Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tocilizumab in Febrile infection-related epilepsy syndrome (FIRES) (2 cohorts), sponsored by Peking University First Hospital. Primary endpoint: Effective rate of seizure reduction after tocilizumab treatment. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
Febrile infection-related epilepsy syndrome (FIRES)
Beyond the preview
Go deeper on ChiCTR2400085185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085185.